The therapeutic landscape for non–small cell lung cancer (NSCLC) has been relatively stable since the 2016 approval of pembrolizumab, but results presented at the 2024 World Conference on Lung ...

Drs. Fatemeh Ardeshir-Larijani and Mohamed Abazeed discuss a validated AI model that can predict how patients with advanced ...

Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, ...

Panelists discuss how both amivantamab plus lazertinib and osimertinib-based regimens show good central nervous system (CNS) ...

The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

The approval of sunvozertinib, an oral irreversible EGFR inhibitor, was supported by data from the WU-KONG1B trial (ClinicalTrials.gov Identifier: NCT03974022 ). The primary efficacy population ...

Patients on baseline steroids had lower ORR, and markedly shorter PFS survival and OS compared with those not receiving ...

TROPION-Lung14: a phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer ...

The global non-small cell lung carcinoma market is poised for significant expansion over the next decade, according to new industry projections. Valued at USD 8.25 billion in 2023, the NSCLC market is ...